HUTCHMED (00013) Holds Investor Meeting to Share Latest R&D Progress and Pipeline Updates

Stock News

昨天

HUTCHMED (00013) announced key updates on its research and business developments during an investor meeting held on October 31, 2025. The event highlighted the company's advancements in innovative therapies for cancer and immune-related diseases, including its next-generation Antibody Targeted Therapeutics Conjugate (ATTC) platform and progress in late-stage pipeline candidates.

Dr. Shi Ming, Chief Medical Officer and Head of R&D at HUTCHMED, stated, "Addressing critical unmet medical needs in oncology and immunology remains central to HUTCHMED's mission, driving our commitment to pioneering novel treatments. The ATTC platform has the potential to redefine precision cancer therapy, and with our robust pipeline and collaborative strategy, we are confident in delivering potentially transformative therapies for patients worldwide."

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1174885812"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174885812\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174885812?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 08:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174885812","market":"sg","top_or_hot":-1,"title":"HUTCHMED (00013) Holds Investor Meeting to Share Latest R&D Progress and Pipeline Updates","media":"Stock News","content":"<p>HUTCHMED (00013) announced key updates on its research and business developments during an investor meeting held on October 31, 2025. The event highlighted the company's advancements in innovative therapies for cancer and immune-related diseases, including its next-generation Antibody Targeted Therapeutics Conjugate (ATTC) platform and progress in late-stage pipeline candidates.</p>\n<p>Dr. Shi Ming, Chief Medical Officer and Head of R&D at HUTCHMED, stated, \"Addressing critical unmet medical needs in oncology and immunology remains central to HUTCHMED's mission, driving our commitment to pioneering novel treatments. The ATTC platform has the potential to redefine precision cancer therapy, and with our robust pipeline and collaborative strategy, we are confident in delivering potentially transformative therapies for patients worldwide.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED (00013) Holds Investor Meeting to Share Latest R&D Progress and Pipeline Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (00013) Holds Investor Meeting to Share Latest R&D Progress and Pipeline Updates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-11-03 08:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>HUTCHMED (00013) announced key updates on its research and business developments during an investor meeting held on October 31, 2025. The event highlighted the company's advancements in innovative therapies for cancer and immune-related diseases, including its next-generation Antibody Targeted Therapeutics Conjugate (ATTC) platform and progress in late-stage pipeline candidates.</p>\n<p>Dr. Shi Ming, Chief Medical Officer and Head of R&D at HUTCHMED, stated, \"Addressing critical unmet medical needs in oncology and immunology remains central to HUTCHMED's mission, driving our commitment to pioneering novel treatments. The ATTC platform has the potential to redefine precision cancer therapy, and with our robust pipeline and collaborative strategy, we are confident in delivering potentially transformative therapies for patients worldwide.\"</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"","article_id":"1174885812","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174885812","pubTimestamp":1762128739,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HUTCHMED (00013) announced key updates on its research and business developments during an investor meeting held on October 31, 2025. The event highlighted the company's advancements in innovative...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","00013":"和黄医药","BK4588":"碎股","BK4531":"中概回港概念","BK1587":"次新股","BK1588":"回港中概股","BK4585":"ETF&股票定投概念","BK4007":"制药","HCM":"和黄医药"},"translate_title":"和黄医药(00013)召开投资者见面会分享最新研发进展及管线更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"HCM":1},"content_text":"HUTCHMED (00013) announced key updates on its research and business developments during an investor meeting held on October 31, 2025. The event highlighted the company's advancements in innovative therapies for cancer and immune-related diseases, including its next-generation Antibody Targeted Therapeutics Conjugate (ATTC) platform and progress in late-stage pipeline candidates.\nDr. Shi Ming, Chief Medical Officer and Head of R&D at HUTCHMED, stated, \"Addressing critical unmet medical needs in oncology and immunology remains central to HUTCHMED's mission, driving our commitment to pioneering novel treatments. The ATTC platform has the potential to redefine precision cancer therapy, and with our robust pipeline and collaborative strategy, we are confident in delivering potentially transformative therapies for patients worldwide.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}